Display options
Cite
Turpie AG. New Therapeutic Opportunities for Heparins: What Does Low Molecular Weight Heparin Offer?. J Thromb Thrombolysis. 1996;3(2):145-149doi: 10.1007/BF00132407.
Turpie, A. G. (1996). New Therapeutic Opportunities for Heparins: What Does Low Molecular Weight Heparin Offer?. Journal of thrombosis and thrombolysis, 3(2), 145-149. https://doi.org/10.1007/BF00132407
Turpie. "New Therapeutic Opportunities for Heparins: What Does Low Molecular Weight Heparin Offer?." Journal of thrombosis and thrombolysis vol. 3,2 (1996): 145-149. doi: https://doi.org/10.1007/BF00132407
Turpie AG. New Therapeutic Opportunities for Heparins: What Does Low Molecular Weight Heparin Offer?. J Thromb Thrombolysis. 1996;3(2):145-149. doi: 10.1007/BF00132407. PMID: 10602555.
Copy Download .nbib Format: NLM
Share it on

J Thromb Thrombolysis. 1996;3(2):145-149. doi: 10.1007/BF00132407.

New Therapeutic Opportunities for Heparins: What Does Low Molecular Weight Heparin Offer?.

Journal of thrombosis and thrombolysis

Turpie

Affiliations

  1. McMaster University, Hamilton, Ontario, Canada.

PMID: 10602555 DOI: 10.1007/BF00132407

Abstract

New advances in antithrombotic therapy include direct thrombin inhibitors and low molecular weight heparins and heparinoids. Low molecular weight heparins and heparinoids have improved pharmacologic and pharmacokinetic properties when compared with unfractionated heparin. Low-molecular weight heparins are effective in the prevention of venous thromboembolism in general surgical patients, orthopedic patients, spinal cord injury patients, and general medical patients. At equipotent antithrombotic doses, low molecular weight heparins produce less bleeding. Low molecular weight heparins given in fixed doses subcutaneously have been shown to be as effective or more effective and safer than unfractionated heparin given intravenously with regular monitoring in the treatment of venous thromboembolic disease. Recent studies have demonstrated that low molecular weight heparins are effective in reducing the risk of death and myocardial infarction in patients with unstable angina and are as effective as intravenous heparin when given subcutaneously without monitoring. Preliminary data indicate that low molecular weight heparins may be effective in improving outcomes in patients with ischemic stroke.

References

  1. Circulation. 1993 Nov;88(5 Pt 1):2045-8 - PubMed
  2. Lancet. 1992 Jul 18;340(8812):152-6 - PubMed
  3. N Engl J Med. 1996 Mar 14;334(11):682-7 - PubMed
  4. Lancet. 1986 Dec 6;2(8519):1293-6 - PubMed
  5. N Engl J Med. 1992 Jan 30;326(5):310-8 - PubMed
  6. N Engl J Med. 1996 Mar 14;334(11):677-81 - PubMed
  7. N Engl J Med. 1992 Jul 16;327(3):141-5 - PubMed
  8. Lancet. 1981 Jun 6;1(8232):1225-8 - PubMed
  9. Thromb Haemost. 1991 Mar 4;65(3):251-6 - PubMed
  10. J Lab Clin Med. 1993 Oct;122(4):364-73 - PubMed
  11. Thromb Haemost. 1985 Dec 17;54(4):813-7 - PubMed
  12. Lancet. 1996 Mar 2;347(9001):561-8 - PubMed
  13. N Engl J Med. 1988 May 5;318(18):1162-73 - PubMed
  14. Chest. 1995 Oct;108(4 Suppl):335S-351S - PubMed
  15. N Engl J Med. 1990 May 3;322(18):1260-4 - PubMed
  16. N Engl J Med. 1995 Dec 14;333(24):1588-93 - PubMed
  17. Am Heart J. 1988 Apr;115(4):850-61 - PubMed
  18. J Am Coll Cardiol. 1995 Aug;26(2):313-8 - PubMed
  19. N Engl J Med. 1991 May 30;324(22):1565-74 - PubMed
  20. N Engl J Med. 1992 Nov 19;327(21):1485-9 - PubMed
  21. N Engl J Med. 1991 Jun 27;324(26):1865-75 - PubMed
  22. Lancet. 1992 Feb 22;339(8791):441-5 - PubMed
  23. Blood. 1992 Jan 1;79(1):1-17 - PubMed
  24. Circulation. 1994 Jan;89(1):81-8 - PubMed
  25. N Engl J Med. 1988 Oct 27;319(17):1105-11 - PubMed
  26. N Engl J Med. 1992 Apr 9;326(15):975-82 - PubMed
  27. Haemostasis. 1986;16 Suppl 2:30-7 - PubMed
  28. Arch Intern Med. 1995 Mar 27;155(6):601-7 - PubMed

Publication Types